公开(公告)号：US11464781B2

公开(公告)日：2022-10-11

申请号：US13203365

申请日：2010-02-24

申请人： Robert Davis ,  Allen Fienberg

发明人： Robert Davis ,  Allen Fienberg

IPC分类号： A61K31/535 ,  A61K9/00 ,  A61K31/5575 ,  A61P27/06

摘要： Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.

公开(公告)号：US20110312978A1

公开(公告)日：2011-12-22

申请号：US13203365

申请日：2010-02-24

申请人： Robert Davis ,  Allen Fienberg

发明人： Robert Davis ,  Allen Fienberg

IPC分类号： A61K31/519 ,  A61P27/02 ,  A61P27/06 ,  C07D487/20 ,  C07D487/14

CPC分类号： A61K31/535

摘要： Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.

摘要翻译： 抑制磷酸二酯酶1（PDE1）的化合物可用于治疗青光眼或升高的眼内压。 PDE1抑制剂可以作为单一疗法或与额外的眼压降低剂组合施用。 此外，本发明提供了包含PDE 1抑制剂和任选的一种或多种另外的眼内压降剂的眼用组合物。 可以使用局部和全身治疗。

公开(公告)号：US08598119B2

公开(公告)日：2013-12-03

申请号：US12994560

申请日：2009-05-27

申请人： Sharon Mates ,  Allen Fienberg ,  Lawrence Wennogle

发明人： Sharon Mates ,  Allen Fienberg ,  Lawrence Wennogle

IPC分类号： A61K38/27 ,  A61K31/56 ,  A61K31/55 ,  A61K31/535 ,  A61K31/50 ,  A61K31/495 ,  A61P5/06 ,  A01N45/00 ,  A01N43/00 ,  A01N43/46 ,  A01N43/62 ,  A01N43/58 ,  A01N43/60

CPC分类号： A61K31/4985 ,  A61K9/0053 ,  A61K31/198 ,  A61K31/44 ,  A61K31/5383 ,  A61K45/06 ,  C07D471/14 ,  C07D498/14

摘要： Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.

公开(公告)号：US20110071080A1

公开(公告)日：2011-03-24

申请号：US12994560

申请日：2009-05-27

申请人： Sharon Mates ,  Allen Fienberg ,  Lawrence Wennogle

发明人： Sharon Mates ,  Allen Fienberg ,  Lawrence Wennogle

IPC分类号： A61K38/27 ,  A61K31/5383 ,  A61K31/4985 ,  A61K31/56 ,  A61K31/5513 ,  A61K31/55 ,  A61P25/18 ,  A61P25/24 ,  A61P25/16 ,  A61P25/14 ,  A61P25/00

CPC分类号： A61K31/4985 ,  A61K9/0053 ,  A61K31/198 ,  A61K31/44 ,  A61K31/5383 ,  A61K45/06 ,  C07D471/14 ,  C07D498/14

摘要： Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.

摘要翻译： 公开了使用特定的取代的杂环稠合的γ-咔啉化合物作为药物和包含它们的药物组合物用于治疗涉及5-HT2A，SERT和/或多巴胺D2途径的一种或多种病症。 此外，化合物可以与其它治疗剂组合用于治疗一种或多种睡眠障碍，抑郁症，精神病，运动障碍和/或帕金森病或任何组合。